Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cymbalta Superior To SSRIs, Lilly Says; Once-Daily Dosing Not Vital To Uptake

Executive Summary

Lilly's pending SNRI Cymbalta induces remission from depression more often than selective serotonin reuptake inhibitors, Exec VP-Science & Technology Steven Paul, MD, said

You may also be interested in...



Lilly Expects Full GMP Inspection After Upgrades To “Building 105”

Lilly is planning to shut down its "Building 105" manufacturing facility in 2004 to make GMP upgrades, CEO Sidney Taurel said during a Dec. 3 analyst dinner in New York

Lilly GMPs Clear One Milestone; Cymbalta Launch Now Planned For Summer

Lilly plans to launch Cymbalta in summer 2004, pending a pre-approval inspection and the build-up of sufficient product inventory

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

Topics

UsernamePublicRestriction

Register

PS044277

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel